To include your compound in the COVID-19 Resource Center, submit it here.

Tecentriq atezolizumab: Additional Phase II data

Data from a cohort 1 of the open-label, international Phase II IMvigor210 trial in 119 evaluable patients with locally advanced or metastatic urothelial carcinoma in

Read the full 258 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE